A New Frontier in Biomarker Discovery - October 4, 2022

A New Frontier in Biomarker Discovery - October 4, 2022

🎙 Anthony Schmitt, PhD 👥 1K 📅 November 9, 2022 ⏱ 31 min 👁 965 📄 expert opinion 🧭 2026-08-18
Available in: English (current) Français

Keywords

3D genomicsHi-Cstructural variantsgene fusionsbiomarker discovery

Summary

In this webinar, Anthony Schmitt, SVP of Science at Arima Genomics, presents the application of 3D genomics (Hi-C) to biomarker discovery and precision oncology. He explains the technology’s ability to detect structural variants, particularly gene fusions, by capturing the spatial proximity of DNA segments. The presentation includes a clinical case of a pediatric brain tumor where a novel PD-L1 fusion was identified, leading to successful off-label treatment with pembrolizumab. Schmitt then presents concordance data with other technologies (FISH, RNA panels) across various tumor types, and highlights the technology’s utility in finding fusions in driver-negative tumors. He reports that in a cohort of 140 driver-negative cases, 33% had fusions associated with FDA-approved therapies, and 6% with therapies in trials. The talk concludes with prospective cases and emphasizes the potential of 3D genomics to uncover novel therapeutic targets.

136 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable insights into a novel technology for detecting structural variants, with a strong emphasis on clinical applications. The argumentation is supported by case studies and aggregate data, though it is presented from a company perspective, which may introduce bias. The speaker effectively explains the technical basis of 3D genomics and its advantages over traditional methods, such as increased sensitivity and the ability to detect fusions missed by other assays.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is generally high, with references to peer-reviewed publications and collaborations with major institutions (NYU, Scripps, Children’s Mercy, MSK). The sources cited are primarily the speaker’s own work and company data, which are not independently verified. The title accurately reflects the content, focusing on biomarker discovery using 3D genomics. The presentation includes a Q&A session, but no comments are provided for analysis.

151 words

Title / Content Match

The title accurately reflects the content, which focuses on using 3D genomics for biomarker discovery.

Quality & Reliability

8/10

Presentation by a scientist with a PhD, based on peer-reviewed research and clinical data, but with a commercial interest in promoting the company's technology.

Key Moments

Cited Sources

Concurring Sources

  • Arima Genomics publications — List of peer-reviewed publications using Arima's technology.

Contribution & Novelties

The presentation highlights the novel application of 3D genomics for biomarker discovery, particularly in identifying gene fusions that are missed by standard DNA/RNA sequencing. The technology offers a unique advantage by capturing spatial proximity, leading to higher sensitivity and the ability to detect fusions in archival samples. The data presented on driver-negative tumors suggests a significant potential for improving patient stratification and identifying therapeutic targets.

Pour aller plus loin :

96 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, indicating a well-balanced presentation suitable for a scientific audience.

Reliability 8/10